Status:
NOT_YET_RECRUITING
Comparing BTVA and MWA in COPD With Early Lung Cancer: Efficacy and Safety
Lead Sponsor:
Henan Provincial People's Hospital
Conditions:
Copd
Lung Cancer
Eligibility:
All Genders
35-80 years
Phase:
NA
Brief Summary
Based on the advantages of BTVA in the treatment of early-stage lung cancer and COPD, researchers propose the concept of using BTVA to treat COPD combined with early-stage lung cancer. Researchers pla...
Detailed Description
Chronic obstructive pulmonary disease (COPD) is a common respiratory disease, affecting nearly 100 million people in China, with the highest mortality rate globally. It is strongly associated with lun...
Eligibility Criteria
Inclusion
- Subjects meeting all of the following criteria are eligible for inclusion:
- Patients of any gender aged between 35 and 80 years with a diagnosis of chronic obstructive pulmonary disease (COPD);
- Chest CT showing ground-glass nodules (GGNs) with a solid/tumor ratio (CTR) ≤ 0.25;
- Nodule size \< 2cm located in the upper lobes of both lungs;
- Pathologically diagnosed as primary peripheral lung cancer, with preoperative clinical staging indicating T1a, bN0M0;
- Investigator assessment that ablative techniques can be feasibly implemented via bronchoscopic or percutaneous approaches to reach the lesion;
- Patients unable to undergo surgery or refuse surgery and are unwilling or intolerant to radiation or chemotherapy;
- Signing an informed consent form, understanding, and actively cooperating with follow-up procedures
Exclusion
- Subjects meeting any of the following conditions are ineligible for inclusion:
- Bronchoscopy contraindications, such as:
- Myocardial infarction within the past month, unstable myocardial ischemia, ejection fraction (EF) ≤40%
- Active hemoptysis
- Coagulation disorders
- Severe hepatic, renal, cardiac, pulmonary, or cerebral dysfunction, severe anemia, dehydration, and severe nutritional disturbances that cannot be corrected or improved in the short term
- Pulmonary function reports indicating FEV1 ≤ 20% predicted value, or DLCO ≤ 20%;
- Respiratory tract infection or acute exacerbation of chronic obstructive pulmonary disease within the preceding 6 weeks before screening;
- Presence of large bullae in the lobe containing the target lung segment/subsegment (defined as bullae occupying more than 1/3 of the lobe) or paraseptal emphysema;
- High-density emphysematous changes simultaneously present in the upper and lower lobes of the contralateral lung, defined as HRCT showing low attenuation areas (\<-950 HU) comprising more than 40% of the total lung volume;
- Tumor located within 2cm of the trachea, main bronchi, esophagus, aortic arch branches, main pulmonary artery, left and right pulmonary arteries, or heart, and within 1cm of the nearest pleural boundary;
- Active pathogenic infection or evidence of active infection (e.g., fever, elevated white cell count), poorly controlled infectious or inflammatory conditions around the lesion or at the puncture site;
- Discontinuation of anticoagulant and/or antiplatelet medications (excluding new oral anticoagulants such as dabigatran, rivaroxaban) for less than 5-7 days before surgery;
- Coexisting conditions or medication use increasing the risk of post-treatment complications, including but not limited to: autoimmune disorders, clinically significant immunosuppressants, history of asthma, α-1 antitrypsin deficiency;
- Daily prednisolone intake exceeding 10mg or an equivalent dose of glucocorticoids during the screening visit;
- History of cardiac or pulmonary transplantation, surgical lung volume reduction, median sternotomy, endoscopic lung volume reduction (e.g., valves, coils), lobectomy, or lung resection;
- Eastern Cooperative Oncology Group (ECOG) score \>2;
- Participation in or currently involved in other clinical studies within the past 30 days;
- Other conditions deemed unsuitable for participation by the investigator.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT06929390
Start Date
May 1 2025
End Date
December 31 2028
Last Update
April 18 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.